Dual inhibition of the renin system by aliskiren and valsartan

被引：16
作者：
Birkenhaeger, Willem H.
Staessen, Jan A. [1 ]
机构：
[1] Univ Leuven, Dept Cardiovasc Dis, Div Hypertens & Cardiovasc Rehabil, Studies Coordinating Ctr, BE-3000 Louvain, Belgium
[2] Erasmus Univ, Rotterdam, Netherlands
来源：
LANCET | 2007年 / 370卷 / 9583期
关键词：
CONVERTING-ENZYME-INHIBITORS; RECEPTOR BLOCKERS; ANGIOTENSIN; COMBINATION; THERAPY; DISEASE;
D O I：
10.1016/S0140-6736(07)61099-X
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：195 / 196
页数：2
相关论文
共 12 条
  • [1] Hyperkalemia in hospitalized patients -: Causes, adequacy of treatment, and results of an attempt to improve physician compliance with published therapy guidelines
    Acker, CG
    Johnson, JP
    Palevsky, PM
    Greenberg, A
    [J]. ARCHIVES OF INTERNAL MEDICINE, 1998, 158 (08) : 917 - 924
  • [2] Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2
    Ferrario, CM
    Jessup, J
    Chappell, MC
    Averill, DB
    Brosnihan, KB
    Tallant, EA
    Diz, DI
    Gallagher, PE
    [J]. CIRCULATION, 2005, 111 (20) : 2605 - 2610
  • [3] HIGGINS B, 2006, MANAGEMENT HYPERTENS
  • [4] Combination therapy with an angiotensin receptor blocker and an ACE inhibitor in proteinuric renal disease: A systematic review of the efficacy and safety data
    MacKinnon, Martin
    Shurraw, Sabin
    Akbari, Ayub
    Knoll, Greg A.
    Jaffey, James
    Clark, Heather D.
    [J]. AMERICAN JOURNAL OF KIDNEY DISEASES, 2006, 48 (01) : 8 - 20
  • [5] Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors:: the CHARM-Added trial
    McMurray, JJV
    Östergren, J
    Swedberg, K
    Granger, CB
    Held, P
    Michelson, EL
    Olofsson, B
    Yusuf, S
    Pfeffer, MA
    [J]. LANCET, 2003, 362 (9386) : 767 - 771
  • [6] Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial
    Oparil, Suzanne
    Yarows, Steven A.
    Patel, Samir
    Fang, Hui
    Zhang, Jack
    Satlin, Andrew
    [J]. LANCET, 2007, 370 (9583) : 221 - 229
  • [7] Laboratory monitoring of potassium and creatinine in ambulatory patients receiving angiotensin converting enzyme inhibitors and angiotensin receptor blockers
    Raebel, Marsha A.
    McClure, David L.
    Simon, Steven R.
    Chan, K. Arnold
    Feldstein, Adrianne
    Andrade, Susan E.
    Lafata, Jennifer Elston
    Roblin, Douglas
    Davis, Robert L.
    Gunter, Margaret J.
    Platt, Richard
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2007, 16 (01) : 55 - 64
  • [8] RISE IN PLASMA-CONCENTRATION OF ALDOSTERONE DURING LONG-TERM ANGIOTENSIN(II)SUPPRESSION
    STAESSEN, J
    LIJNEN, P
    FAGARD, R
    VERSCHUEREN, LJ
    AMERY, A
    [J]. JOURNAL OF ENDOCRINOLOGY, 1981, 91 (03) : 457 - 465
  • [9] Oral renin inhibitors
    Staessen, Jan A.
    Li, Yan
    Richart, Tom
    [J]. LANCET, 2006, 368 (9545) : 1449 - 1456
  • [10] Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating Telmisartan, Ramipril, and their combination in high-risk patients: The Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND) trials
    Teo, KK
    [J]. AMERICAN HEART JOURNAL, 2004, 148 (01) : 52 - 61
12